Filippo Giancotti, MD, PhD. 哥伦比亚大学资深遗传学教授，Herbert Irving Comprehensive Cancer Center主任。Giancotti教授是Cell adhesion/Integrin 信号研究的鼻祖，深耕Integrin信号通路研究三十多年。此次合作主要是希格生科将其与Integrin相关的first-in-class的创新靶向药在Giancotti教授的关于乳腺癌转化研究中的应用。
Filippo Giancotti教授简介
Filippo Giancotti, MD, PhD. 哥伦比亚大学资深遗传学教授，Herbert Irving Comprehensive Cancer Center主任。Giancotti教授是Cell adhesion/Integrin 信号研究的鼻祖，深耕Integrin信号通路研究三十多年。此次合作主要是希格生科将其与Integrin相关的first-in-class的创新靶向药在Giancotti教授的关于乳腺癌转化研究中的应用。
Filippo Giancotti教授简介
Dr. Giancotti has received many honors and recognitions for his contributions to the field of oncology, including the National Cancer Institute’s Outstanding Investigator Award and an Established Investigators Award from the Cancer Prevention and Research Institute of Texas. He joins the HICCC from MD Anderson Cancer Center at the University of Texas where he served as the scientific director of the Koch Center and co-leader of the Prostate Cancer Moonshot. He previously held positions at Memorial Sloan Kettering Cancer Center and Weill Cornell. At MD Anderson, Dr. Giancotti established a translational research program on breast, prostate, and pancreatic cancer metastasis. He earned his medical degree with honors and his doctoral degree in cell biology from the University of Turin School of Medicine in Italy. He received board certification in hematology and oncology from the University of Rome.
关于希格生科
希格生科（Signet Therapeutics）是一家基于疾病模型的癌症创新靶向药研发公司。希格生科成立于2020年底，其最初创立于哈佛大学校园，核心团队由来自哈佛大学、麻省理工学院和中国科学院等学术界以及医药产业界的优秀人才组成。总部设立在深圳，并在美国波士顿设有分部。希格不仅是Signet的音译，而且秉承“希冀满怀，格物致知”的愿景，通过公司团队专业、前沿以及追求极致的努力，让目前无药可用的癌症病人满怀希望，并且致力于通过精准靶向治疗将高致死性的恶性癌症变成可管理的慢性疾病而不懈努力。